ArticleScientific reports2026
An interpretable radiomics-machine learning model for early risk stratification of invasive fungal infections in community-acquired pneumonia: a dual-center study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
To develop and validate an interpretable HRCT radiomics-based machine learning model for early risk stratification and identification of invasive fungal infection (IFI) in patients with community-acquired pneumonia (CAP). A total of 570 CAP patients who underwent HRCT from July 2022 to August 2024 in Center 1 and Center 2 were recruited. A VB-net pneumonia automatic segmentation algorithm was employed. Three models, a radiomics model (HRCT-derived radiomics features), a clinical model (clinical variables), and a combined model (integrating both), were developed. The performance of the model was evaluated through receiver operating characteristic analysis with respect to the area under the curve (AUC). Clinical utility was evaluated by using decision curve analysis. The Shapley Additive Explanations tool was employed. A total of 239 (mean age: 62.1 ± 19.3 years; 134 male), 101 (mean age: 57.5 ± 17.3 years; 44 male), and 230 (mean age: 68.4 ± 15.3 years; 153 male) patients were included in the training, internal validation, and external validation datasets, respectively. Based on the linear discriminant analysis classifier, the AUCs of the clinical, radiomics, and combined models were 0.719, 0.724, and 0.808, respectively, in the internal validation dataset; and 0.707, 0.709, and 0.786, respectively, in the external validation dataset. The combined model yielded a superior net benefit relative to both the clinical and radiomics models alone. Age exerted the greatest influence on the predictions of the combined model, while the top three influential radiomics features were all high-order texture features. A radiomics-based machine learning model provides moderate incremental value as an adjunctive tool for early IFI risk stratification in patients with CAP before definitive microbiological or pathological confirmation, with favorable interpretability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.